AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference

Before you go, we thought you'd like these...
Before you go close icon

AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NAS: AMAG) today announced that William Heiden, AMAG's chief executive officer, will participate in the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at 2:00 pm Eastern Time. The presentation will include a company overview and business update, followed by a question and answer session with investors.

A live webcast of the presentation will be accessible through the Investors section of the company's website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until March 13, 2013.


About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that manufactures and markets Feraheme® (ferumoxytol) Injection for Intravenous (IV) use in the United States. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers. For additional company information, please visit www.amagpharma.com.



AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

The article AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners